Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 17,036 as of Wednesday, Sept. 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,316 issues advancing vs. 1,661 declining with 150 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include UnitedHealth Group ( UNH), down 1.4%, Universal Health Services ( UHS), down 1.0% and WellPoint ( WLP), down 1.0%. Top gainers within the industry include Grifols ( GRFS), up 1.5%, Boston Scientific ( BSX), up 1.1%, Medtronic ( MDT), up 0.9% and Covidien ( COV), up 0.7%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Quest Diagnostics is down $0.87 (-1.4%) to $62.96 on light volume. Thus far, 372,760 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $62.82-$64.00 after having opened the day at $64.00 as compared to the previous trading day's close of $63.83. Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.3 billion and is part of the health care sector. Shares are up 19.2% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.